Barclays Maintains Overweight on Elevance Health, Raises Price Target to $472
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice TargetHot
Barclays analyst Andrew Mok maintains Elevance Health (NYSE:ELV) with a Overweight and raises the price target from $469 to $472.
Barclays analyst Andrew Mok maintains Elevance Health (NYSE:ELV) with a Overweight and raises the price target from $469 to $472.